Skip to main content

Advertisement

SpringerLink
Log in

Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Recent evidence indicates that vascular endothelial growth factor (VEGF) is capable of protecting dopaminergic (DA) neurons. Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by the degeneration of nigrostriatal dopaminergic neurons. To evaluate the role of VEGF single nucleotide polymorphisms (SNPs) and haplotypes in PD, we performed a case–control study including 400 PD patients and 400 healthy-matched controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) analysis and DNA sequencing were used to detect the rs699947, rs2010963 and rs3025039 polymorphisms of the VEGF gene in cases and controls. Our study revealed that T allelic frequency of rs3025039 polymorphism was significantly higher in PD subjects (OR 1.497, 95 % CI 1.099–2.040, P = 0.013) than that in controls. Significant association for rs3025039 could be found in additive model (TT vs. CT vs. CC: OR 1.489, 95 % CI 1.018–2.177, P = 0.040) and dominant model (TT + CT vs. CC: OR 1.538, 95 % CI 1.068–2.216, P = 0.021). Subgroup analyses performed by gender suggested that this association could be found in male, but not in female. Moreover, it also demonstrated a significant association in the subgroup of late-onset PD (LOPD). However, for rs699947 and rs2010963 polymorphisms, genotype or allele frequencies did not differ between groups. No significant association could be found between rs699947 and rs2010963 polymorphism and PD risk. None of the observed haplotypes showed significant association with PD. Therefore, these results suggested that the VEGF gene might be associated with risk of developing sporadic PD in Han Chinese and the rs3025039 polymorphism may be a risk factor for sporadic PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144. doi:10.1016/j.freeradbiomed.2013.01.018

    Article  CAS  PubMed  Google Scholar 

  2. Bartels AL, Leenders KL (2009) Parkinson’s disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45(8):915–921. doi:10.1016/j.cortex.2008.11.010

    Article  PubMed  Google Scholar 

  3. Rosenstein JM, Krum JM (2004) New roles for VEGF in nervous tissue–beyond blood vessels. Exp Neurol 187(2):246–253. doi:10.1016/j.expneurol.2004.01.022

    Article  CAS  PubMed  Google Scholar 

  4. Storkebaum E, Carmeliet P (2004) VEGF: a critical player in neurodegeneration. J Clin Investig 113(1):14–18. doi:10.1172/jci20682

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Quittet MS, Touzani O, Sindji L, Cayon J, Fillesoye F, Toutain J, Divoux D, Marteau L, Lecocq M, Roussel S, Montero-Menei CN, Bernaudin M (2015) Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat. Acta Biomater 15:77–88. doi:10.1016/j.actbio.2014.12.017

    Article  CAS  PubMed  Google Scholar 

  6. Krum JM, Mani N, Rosenstein JM (2008) Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Exp Neurol 212(1):108–117. doi:10.1016/j.expneurol.2008.03.019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nowacka MM, Obuchowicz E (2012) Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 46(1):1–10. doi:10.1016/j.npep.2011.05.005

    Article  CAS  PubMed  Google Scholar 

  8. Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neuro-Signals 14(5):207–221. doi:10.1159/000088637

    Article  CAS  PubMed  Google Scholar 

  9. Falk T, Yue X, Zhang S, McCourt AD, Yee BJ, Gonzalez RT, Sherman SJ (2011) Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson’s disease. Neurosci Lett 496(1):43–47. doi:10.1016/j.neulet.2011.03.088

    Article  CAS  PubMed  Google Scholar 

  10. Piltonen M, Planken A, Leskela O, Myohanen TT, Hanninen AL, Auvinen P, Alitalo K, Andressoo JO, Saarma M, Mannisto PT (2011) Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Neuroscience 192:550–563. doi:10.1016/j.neuroscience.2011.06.084

    Article  CAS  PubMed  Google Scholar 

  11. Yasuhara T, Shingo T, Muraoka K, Wen Ji Y, Kameda M, Takeuchi A, Yano A, Nishio S, Matsui T, Miyoshi Y, Hamada H, Date I (2005) The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson’s disease model. Brain Res 1038(1):1–10. doi:10.1016/j.brainres.2004.12.055

    Article  CAS  PubMed  Google Scholar 

  12. Yasuda T, Fukuda-Tani M, Nihira T, Wada K, Hattori N, Mizuno Y, Mochizuki H (2007) Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson’s disease. Exp Neurol 206(2):308–317. doi:10.1016/j.expneurol.2007.05.012

    Article  CAS  PubMed  Google Scholar 

  13. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I (2005) Neurorescue effects of VEGF on a rat model of Parkinson’s disease. Brain Res 1053(1–2):10–18. doi:10.1016/j.brainres.2005.05.027

    Article  CAS  PubMed  Google Scholar 

  14. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46(3):293–298. doi:10.1016/j.lungcan.2004.04.037

    Article  PubMed  Google Scholar 

  15. Samli H, Demir BC, Ozgoz A, Atalay MA, Uncu G (2012) Vascular endothelial growth factor gene 1154 G/A, 2578 C/A, 460 C/T, 936 C/T polymorphisms and association with recurrent pregnancy losses. Genet Mol Res: GMR 11(4):4739–4745. doi:10.4238/2012.December.17.6

    Article  CAS  PubMed  Google Scholar 

  16. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235. doi:10.1006/cyto.2000.0692

    Article  CAS  PubMed  Google Scholar 

  17. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471. doi:10.1002/ijc.11238

    Article  CAS  PubMed  Google Scholar 

  18. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, Virgilio R, Galimberti D, Galimberti G, Crimi M, Ferrarese C, Scarpini E, Bresolin N, Comi GP (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57(3):373–380. doi:10.1002/ana.20390

    Article  CAS  PubMed  Google Scholar 

  19. Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, Taylor JA (2004) VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J Neurogenet 18(2):429–434. doi:10.1080/01677060490894450

    Article  CAS  PubMed  Google Scholar 

  20. Mihci E, Ozkaynak SS, Sallakci N, Kizilay F, Yavuzer U (2011) VEGF polymorphisms and serum VEGF levels in Parkinson’s disease. Neurosci Lett 494(1):1–5. doi:10.1016/j.neulet.2011.02.027

    Article  CAS  PubMed  Google Scholar 

  21. Kim JS, Yim SV, Koh IS, Choi JS, Yoo JY, Lee KS, Lim Y, Lee KH (2009) Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer. Arch Gerontol Geriatr 48(3):287–290. doi:10.1016/j.archger.2008.02.007

    Article  CAS  PubMed  Google Scholar 

  22. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP (2009) VEGF genetic variability is associated with increased risk of developing Alzheimer’s disease. J Neurol Sci 283(1–2):66–68. doi:10.1016/j.jns.2009.02.318

    PubMed  Google Scholar 

  23. Yuan Q, Zuo X, Jia J (2009) Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer’s disease among Northern Chinese Han. Neurosci Lett 457(3):133–136. doi:10.1016/j.neulet.2009.03.078

    Article  CAS  PubMed  Google Scholar 

  24. Chapuis J, Tian J, Shi J, Bensemain F, Cottel D, Lendon C, Amouyel P, Mann D, Lambert JC (2006) Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer’s disease. Neurobiol Aging 27(9):1212–1215. doi:10.1016/j.neurobiolaging.2005.07.013

    Article  CAS  PubMed  Google Scholar 

  25. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Sanchez-Quintana C, Sanchez-Juan P, Berciano J, Combarros O (2006) Case–control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer’s disease. Neurosci Lett 401(1–2):171–173. doi:10.1016/j.neulet.2006.03.020

    Article  CAS  PubMed  Google Scholar 

  26. Vught PWV, Sutedja NA, Veldink JH, Koeleman BP, Groeneveld GJ, Wijmenga C, Uitdehaag BM, Jong JMD, Baas F, Wokke JH, Berg LHVD (2005) Lack of association between VEGF polymorphisms and ALS in a Dutch population. Neurology 22:1643–1645

    Article  Google Scholar 

Download references

Acknowledgments

We are grateful to all of the subjects who kindly agreed to participate in this study. This work was supported by Chinese National Human Genome Center, Beijing. We extend our gratitude to the reviewers for their helpful comments on this paper. This work was supported by grants from Natural Science Foundation of China (81571225).

Author information

Authors and Affiliations

  1. Department of Neurology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266003, Shandong, People’s Republic of China

    Yubin Wu, Yingying Zhang, Xiaoyuan Li & Anmu Xie

  2. Department of Neurology, Chinese PLA General Hospital, Beijing, China

    Xun Han

  3. Department of Rehabilitation, The Affiliated Hospital of Qingdao University, Qingdao, China

    Li Xue

Authors
  1. Yubin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yingying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xun Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anmu Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anmu Xie.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Zhang, Y., Han, X. et al. Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurol Sci 37, 1923–1929 (2016). https://doi.org/10.1007/s10072-016-2691-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2691-x

Keywords

Search

Navigation